Avastin (bevacizumab)

P1/2, N=99, Not yet recruiting, Luye Pharma Group Ltd.

P2/3, N=120, Not yet recruiting, Nanjing Sanhome Pharmaceutical, Co., Ltd.

P2, N=35, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

In OC mice, TRIM28 overexpression promotes angiogenesis and Bev resistance via ESM1-mediated ITGB1/FAK activation. This work unveils a new molecular pathway underlying Bev resistance in OC and proposes TRIM28 and ESM1 as potential therapeutic targets.

Patients with non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations who experience disease progression after treatment with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) often receive subsequent treatment with either platinum-based chemotherapy (Chemo) or a combination regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP). After propensity score matching, among patients who responded to prior EGFR-TKIs for ≥10 months, the ABCP group had a significantly longer PFS than the Chemo group (8.6 versus 5.3 months; log-rank test, P = 0.008). The efficacy of prior EGFR-TKI treatment in patients with EGFR-mutant NSCLC who experience disease progression could be a predictive marker for ABCP rather than Chemo efficacy.

P=N/A, N=350, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Not yet recruiting --> Recruiting

P2, N=62, Active, not recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Oct 2030 --> Sep 2027 | Trial primary completion date: Oct 2029 --> Mar 2026

P2, N=16, Active, not recruiting, Nicholas DeVito, MD | Recruiting --> Active, not recruiting

P2, N=30, Recruiting, Genentech, Inc. | Trial completion date: Nov 2026 --> Dec 2027 | Trial primary completion date: Sep 2026 --> Jul 2027

P3, N=480, Recruiting, University of Campania Luigi Vanvitelli

Management required multidisciplinary coordination and included carboplatin, paclitaxel, and pembrolizumab, followed by radiation to the orbit, iliac crest, and mediastinal sites of disease. Unfortunately, he experienced progression while on maintenance immunotherapy with new rib and brain lesions, for which he underwent treatment with platinum, pemetrexed, and bevacizumab with additional radiotherapy...Our findings underscore the need for ophthalmology, radiation oncology, and medical oncology collaboration when vision-threatening or occult metastatic lesions arise., For readers, the takeaway is that choroidal metastasis-particularly in the era of immunotherapy-warrants individualized, multidisciplinary evaluation rather than default palliation. Our case demonstrates that coordinated multimodality management can achieve long-term disease control, highlighting a treatment paradigm worth considering for selected patients and calling for updated guidelines that reflect modern therapeutic capabilities.

P1/2, N=500, Active, not recruiting, FBD Biologics Limited | Recruiting --> Active, not recruiting | N=150 --> 500